Prevalence of Hypophosphatasia in Patients with Fibromyalgia at the Mayo Clinic

Overview

About this study

The overall goal of this research is to identify patients in clinical practice that have unrecognized hypophosphatasia (HPP) and select appropriate candidates for therapy. The purpose of this proposal is to identify the prevalence of adults with hypophosphatasia within a previously identified fibromyalgia cohort at our institution.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult subjects with fibromyalgia with at least two alkaline phosphatase values below the normal age and sex range.
  • Subjects identified from IRB 13-006618 with possible HPP

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Robert Wermers, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Robert Wermers M.D.

(507)266-0500

Wermers.Robert@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20310579

Mayo Clinic Footer